<DOC>
	<DOCNO>NCT02232607</DOCNO>
	<brief_summary>The aim study explore whether lacidipine dose 2 mg , 4 mg 6 mg decrease symptom angina , compare placebo patient chronic stable angina</brief_summary>
	<brief_title>Efficacy Safety Lacidipine Chronic Stable Angina</brief_title>
	<detailed_description />
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Lacidipine</mesh_term>
	<criteria>Age 18 80 year History stable , exertional angina pectoris ( Canadian Cardiovascular Society functional class II III ) least 3 month duration prior enrolment study Patients currently receive treatment antianginal medication ( shortacting nitrate ) Between visit 2 3 two treadmill exercise test , demonstrate ≥ 0.1 mV horizontal slop STsegment depression , must carry . The difference symptomlimited exercise duration two test must exceed 20 % Total treadmill exercise duration &gt; 3 minute ( i.e . stage 2 standard Bruce protocol ) Coronary artery disease , preferably ( mandatory ) document history proven myocardial infarction and/or coronary angiography indicate ≥ 50 % reduction luminal diameter one coronary artery primary branch Myocardial infarction within 3 month prior enrolment study Percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass surgery within 6 month Other type angina ( variant , unstable ) Uncontrolled hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 100 mmHg ) Resting heart rate &lt; 50 bpm &gt; 100 bpm Significant valvular heart disease Heart failure New York Heart Association Class III IV Chronic obstructive pulmonary disease and/or asthma clinical symptom require regular medication Significant arrhythmia ( since may interfere interpretation electrocardiogram ) include Wolff ParkinsonWhite syndrome , atrial fibrillation , atrial flutter , sick sinus syndrome , significant AtrioVentricular heart block , intraventricular conduction defect ( QRS &gt; 0.12 second ) ventricular preexcitation , bundle branch block , presence pacemaker , presence implant automatic defibrillator , uncorrected hypokalaemia ( potassium &lt; 3.5 mmol/litre ) Insulin dependent diabetes mellitus Significant liver disease ( Aspartate Aminotransferase Alanine Aminotransferase &gt; twice upper limit reference range ) Significant renal disease ( creatinine &gt; 1.5 x upper limit reference range ) Any clinical condition opinion investigator , would preclude safe fulfilment protocol safe administration trial medication Inability perform repeat exercise test due extracardiac reason Concomitant treatment antianginal medication , whether prescribe indication ( e.g . calcium channel blocker , βblockers longacting nitrate ) Concomitant treatment antiarrhythmic medication , digitalis tricyclic antidepressant agent know affect STsegment morphology Known hypersensitivity component investigational drug Pregnant nursing woman woman child bear potential Participation clinical trial within 2 month enrolment History drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>